Yes. Esketamine nasal spray (Spravato) has been reimbursed from the Dutch basic package (basispakket) since 1 September 2021 — for adults with difficult-to-treat unipolar depression who have not responded to at least three medicinal treatment steps in the current episode: two antidepressants plus at least one augmentation strategy. Treatment happens only at specialized centers, many cooperating in the ENC-NL consortium, always via psychiatrist referral, and it counts toward your annual deductible (eigen risico). This page covers who qualifies, who confirms the coverage, what you pay, and what to do if you fall outside the criteria; the eligibility decision itself always sits with a clinician, and you can begin orienting yourself with our eligibility check.
What is covered
After the package advice by Zorginstituut Nederland, esketamine entered the basic package on 1 September 2021. Insurers cover the drug and the treatment sessions — but not at any GGZ practice. The Dutch Psychiatric Association agreed quality criteria for specialized esketamine centers with insurers: experienced psychiatric supervision, somatic monitoring, protocols for dissociation, and structured outcome measurement. Many qualifying centers — academic hospitals and large GGZ institutions — cooperate in the Esketamine Neusspray Consortium (ENC-NL), which also collects national outcome data. Esketamine is always combined with a continuing oral antidepressant, and the acute psychiatric-emergency indication is not reimbursed. Dutch insurers also pioneered outcomes-based, pay-for-performance contracts for esketamine — a funding model, not an extra hurdle for you.
Who qualifies
The Dutch framework is stricter than the EU label, which requires two failed treatments; the Netherlands added an augmentation step. Coverage requires:
- An adult with difficult-to-treat unipolar, non-psychotic depression;
- No response to at least three medicinal treatment steps in the current episode — two antidepressant trials plus at least one augmentation strategy (for example lithium added to an antidepressant), each at adequate dose and duration;
- Esketamine combined with a continuing oral antidepressant.
The practical currency is a written treatment history: every antidepressant and augmentation strategy tried in the current episode, with substance, dose, duration and outcome. Gather old prescriptions, discharge letters and pharmacy records before the assessment rather than after it — it decides more cases than anything else.
Who decides and how to apply
Your GP (huisarts) refers you into specialist GGZ care if you are not already there. A psychiatrist then confirms the diagnosis, documents the three failed steps, and refers you to an esketamine center — ideally one contracted by your insurer. The center confirms coverage with your insurer before starting; patient organizations have documented friction between insurers and prescribers, so let the center manage the paperwork rather than doing it yourself. Waiting lists at centers can run months — ask for the current estimate and discuss bridging options with your psychiatrist. To see which listed providers operate near you, browse providers in the Netherlands; for the full picture of every legal route in the country, see our Netherlands access guide.
What it costs you
For eligible patients, the drug and treatment sessions are covered from the basic package. What you pay is your annual deductible (eigen risico) — treatment counts toward it like other basic-package care. Induction is typically twice weekly for four weeks, then frequency tapers based on measured response, so plan transport for every visit: you must not drive until the next day.
If you do not qualify
- Complete the augmentation step. If you have only tried two antidepressants, your psychiatrist may complete an augmentation trial first — standard practice anyway, and it can bring you inside the criteria.
- Oral esketamine is not a shortcut. Generic oral esketamine is being studied under the Zorginstituut's "promising care" (veelbelovende zorg) scheme. A coverage decision was earlier expected around 2026, but the research now runs to about 2029, and no reimbursement decision exists as of July 2026 — outside the study, oral esketamine is not covered. If a clinician offers it, ask explicitly whether it is inside the study protocol.
- Hospital (es)ketamine units run infusion-based treatment in specialist and research settings via psychiatric referral. The Netherlands has no private ketamine clinic market comparable to the UK or Spain; if you consider any private offer, apply the checks in our clinic-choice guide.
- Clinical trials are free by definition, and the Dutch pipeline is one of Europe's densest — see the trials guide.
Frequently asked questions
Is Spravato reimbursed in the Netherlands?
Yes — it has been in the basic package since 1 September 2021 for difficult-to-treat unipolar depression after two failed antidepressants plus at least one failed augmentation strategy in the current episode. Treatment runs at specialized centers, and your annual deductible (eigen risico) applies.
I have only tried two antidepressants — do I qualify?
Not for reimbursed treatment — the Dutch framework requires the additional augmentation step, which is stricter than the EU label. Your psychiatrist may complete an augmentation trial first, which is standard practice anyway.
Is oral esketamine or a ketamine infusion covered?
Oral esketamine is only available within the Zorginstituut's "promising care" research, which runs to about 2029 — no reimbursement decision has been made as of July 2026. Hospital infusion units operate under specialist or research protocols; private ketamine offerings fall outside the basic package.
How do the Dutch criteria compare with other countries?
The three-step requirement is stricter than the EU label and stricter than Germany's two-antidepressant rule, but the Netherlands covers both the drug and the treatment sessions with no per-patient insurer pre-approval step. See the Europe-wide reimbursement map for the full comparison.
Sources
- Zorginstituut Nederland: Pakketadvies esketamine neusspray (Spravato)
- ENC-NL: Esketamine Neusspray Consortium Nederland
- Zorginstituut Nederland: Veelbelovende zorg — orale esketamine bij ernstige depressie
- GGZ Nieuws: Geen vergoeding esketamine bij acute behandeling
- Blossom: Netherlands country report
- Reimbursement Pathways for Psychedelic Therapies in Europe — Magnetar Access × Blossom (2025)
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.